One of the challenges of gene targeting is to achieve regulated transgene expression in specific target cells. The hypogonadal (hpg) mice are genetically deficient in hypothalamic gonadotropin-releasing hormone (GnRH) production due to a deletion in the GnRH gene, resulting in hypogonadotropic hypogonadism. Here we show an improvement in reproductive parameters of adult female homozygous hpg mice by direct infusion into the hypothalamic preoptic area (POA) of a herpes simplex virus (HSV)-based amplicon vector containing a 13.5 kb genomic fragment encoding the GnRH gene together with its cognate promoter and regulatory elements. Following vector injection, GnRHexpressing neurons were detected in the POA, and pituitary and plasma gonadotropin levels as well as ovarian and uterine weights increased. In addition, a subset of injected hpg mice demonstrated cyclic estrous changes, consistent with regulated control of GnRH production. Administration of kisspeptin-10 resulted in an increase in plasma luteinizing hormone levels, further supporting appropriate regulation of the introduced GnRH transgene. These findings indicate that delivery of the GnRH gene resulted in selective neuronal expression of GnRH and regulated hypothalamic GnRH release. To our knowledge, this is the first example of the correct targeting of a gene under its cognate promoter to neurons resulting in selective and regulated synthesis of a biologically active peptide, and thus may have a wide range of applications in the treatment of human disorders.
Introduction
Virus-based vector systems have been widely used to deliver cDNAs for neurotrophic proteins to the central nervous system (CNS) in experimental animal models and clinical trials. [1] [2] [3] [4] [5] Although successful in many cases, a limitation is that expression of the delivered cDNA is frequently under the control of constitutive viral promoters, such as cytomegalovirus (CMV) immediate early promoter, and thus is expressed in any infected cell, regardless of cell type, frequently at supranormal levels and without appropriate physiologic regulation.
Current cDNA delivery approaches are therefore not appropriate for proteins that need to be expressed in discrete sets of cells under appropriate regulation to be effective. To achieve specificity of delivered gene expression, several gene therapy studies have focused in recent years on cell-type specific promoters. [6] [7] [8] [9] [10] These studies demonstrate that a cell-or tissue-specific promoter in a viral vector can dictate specific expression of a given gene and raise the question of whether gene therapy with a complete gene might achieve regulated gene expression.
A replication-defective herpes simplex virus (HSV)-1-based amplicon vector has a large transgene capacity up to 150 kb, 11, 12 among other advantages, [13] [14] [15] [16] thus making it a useful tool for gene therapy delivering a complete gene. In contrast, adeno-associated virus (AAV) and lentiviral/retroviral vectors are limited in their transgene capacity to approximately 4.5 and 8 kb, respectively. 2, 11 Previous studies have confirmed regulation and alternative splicing of genes delivered by HSV amplicon vectors into cultured cells. 17, 18 The mammalian reproductive system is under the control of gonadotropin-releasing hormone (GnRH), a decapeptide synthesized and released in a tightly regulated pulsatile manner from specific GnRH neurons located in the hypothalamic preoptic area (POA). 19 The hypogonadal (hpg) mouse is mutant mouse strain that is sexually immature in the homozygous null state. 20 The genetic basis for this phenotype is the deletion of over 33.5 kb of the GnRH gene, including exons III and IV. 21 As a result, homozygous hpg mice have no detectable GnRH, low levels of circulating gonadotropins (luteinizing hormone (LH) and follicle-stimulating hormone (FSH)), infantile gonads, and infertility. 20, 21 The detection in the POA of a truncated form of GnRH transcripts that includes exons I and II, albeit at low levels, suggests the existence of POA GnRH neurons despite the absence of the GnRH peptide. 21 Several attempts have been made to rescue hypogonadism in hpg mice, [22] [23] [24] [25] [26] [27] [28] [29] and these studies indicate that the pituitary-gonadal axis in these hpg animals is intact and capable of responding to GnRH.
These hpg mice provide a useful model system for gene transfer studies. Here we have determined that delivery of the GnRH gene with its cognate promoter and exon/intron structure into the POA of hpg mice using an HSV amplicon vector resulted in selective neuronal expression of GnRH and improvement in reproductive parameters, suggesting regulated hypothalamic GnRH expression and pulsatile release. To our knowledge, this is the first study to achieve correct targeting and regulated expression of a gene under its cognate promoter and regulatory elements, thereby providing a novel treatment paradigm with potential human applications.
Results
hpg mice injected with HSV.GnRH.GFP express GnRH in the POA We generated an amplicon vector, HSV.GnRH.GFP, bearing a 13.5 kb mouse genomic fragment encompassing the GnRH gene (Figure 1a) , corresponding to the same fragment used in a previous transgenic study. 26 This amplicon vector also includes a cassette encoding enhanced green fluorescence protein (GFP) driven by the CMV promoter (Figure 1b) . A control amplicon vector, HSV.GFP, containing the GFP cDNA under the CMV promoter but lacking the GnRH gene, was also prepared.
To determine if CNS injection of HSV.GnRH.GFP could lead to GnRH expression, the GnRH or control vector was injected into the medial POA of adult female hpg mice. Immunohistochemistry of the POA of wildtype female mice (positive control) revealed scattered GnRH-positive neurons ( Figure 2A, panel a) . In female hpg mice either without injection or after injection of HSV.GFP (control vector), no GnRH-positive neurons were detected (Figure 2A , panels b-d), consistent with previous observations of hpg mice. 21 However, in female hpg mice injected with the HSV.GnRH.GFP, scattered GnRH-positive neurons were detected 10 and 50 days after injection (Figure 2A , panels e and f).
Similarly, fluorescence microscopy of POA sections immunostained for GnRH revealed that the POA of wild-type female mice contained scattered GnRH-positive neurons (red) ( Figure 2B, panel a) . In contrast, while control HSV.GFP-injected hpg mice showed an abundant distribution of GFP-positive cells (green) in the POA, they showed no detectable GnRH staining ( Figure 2B , panels b and c). In hpg mice injected with HSV.GnRH.GFP, GnRH-positive neurons were again detected 10 and 50 days after injection ( Figure 2B , panels d and e). The locations of the scattered GnRH-positive neurons in these mice were in agreement with the distribution in wild-type mice, including the vascular organ of the lamina terminalis, medial POA, median and ventromedial preoptic nucleus, anteroventral periventricular nucleus and medial septal nucleus. GFP-positive cells were more widely distributed throughout the POA, magnocellular preoptic nucleus, substantia innominata and nucleus of the ventral and horizontal limb of the diagonal band. Control staining in the absence of antiGnRH antibody using brain sections from an hpg mouse 50 days after HSV.GnRH.GFP injection was negative ( Figure 2B , panel f). Colocalization studies revealed that GnRH-positive neurons were also GFP-positive in these mice. No GnRH-positive neurons lacked GFP fluorescence. Notably, however, GnRH fluorescence was detected only in a small subpopulation of the GFP-positive cells. These results suggest that GnRH is selectively expressed under its own cognate promoter in GnRH neurons, whereas GFP is more widely expressed in the area of vector injection under the control of the strong and constitutively active CMV promoter. No ectopic We counted the number of GnRH-positive neurons in fluorescence-stained POA sections from the HSV.GnRH. Figure 3A , panel a). In contrast, in female hpg mice either without injection or following control HSV.GFP injection, LHb-positive cell numbers were substantially reduced ( Figure 3A , panels b and c). In female hpg mice injected with HSV.GnRH.GFP, however, the number of LHb-positive cells significantly increased 50 days post-injection, towards levels seen in control wild-type females ( Figure 3A , panels d and e, and C, panel a). Similarly, anterior pituitary FSHbpositive cells were reduced in female hpg mice compared to wild-type females ( Figure 3B , panels a-c, and C, panel b), and HSV.GnRH.GFP injection increased the number of FSHb-positive cells 50 days after injection ( Figure 3B , panels d and e). These data indicate that HSV.GnRH.GFP injection resulted in increased pituitary gonadotropin production, likely reflecting coordinated pulsatile GnRH secretion from hypothalamic GnRH neurons. 30 hpg mice injected with HSV.GnRH.GFP have increased plasma gonadotropin levels Consistent with previous reports, 24, 26 plasma LH levels were lower in female hpg mice than in wild-type females (Figure 4a ). HSV.GnRH.GFP injection into the POA of female hpg mice significantly increased plasma LH levels at both 10 and 50 days post-injection. Changes in plasma FSH levels had a similar pattern to those of LH, reaching statistically significant increases at 50 days post-injection ( Figure 4b ). Plasma 17b-estradiol levels were also significantly increased by HSV.GnRH.GFP injection, reaching wild-type female levels 50 days post-injection ( Figure 4c ). These results indicate that secretion of pituitary gonadotropins and gonadal steroid hormones is increased following GnRH gene delivery in adult female hpg mice, consistent with downstream pituitary gonadotrope and gonadal responsiveness to GnRH secretion. hpg mice injected with HSV.GnRH.GFP have increased ovarian and uterine weights
We measured ovarian and uterine weights in wild-type, uninjected hpg and vector-injected hpg mice to assess the effect of GnRH gene transfer on maturation of the reproductive organs. Ovarian size and uterine thickness, reflective of actions of circulating estrogens, were increased in the HSV.GnRH.GFP-injected hpg mice by approximately twofold, and combined ovarian and uterine weights were significantly increased 50 days post-injection compared to uninjected hpg mice, although still smaller than those of wild-type females ( Figure 5 ). Adrenal weights, measured as a control, did not change Vaginal cytology in a subset (n ¼ 2/10) of HSV.GnRH. GFP-injected hpg mice demonstrated changes from nonestrus to the typical cornified cells of estrus, signifying the action of increased circulating estrogens (data not shown). These changes were first observed 21 days after injection, which coincided with full maturation of GnRH.GFP-injected hpg mice 10 days (n ¼ 4 and 5, respectively) and 50 days (n ¼ 4 and 6, respectively) postinjection, and wild-type mice (n ¼ 3). The number of positive pituitary cells was counted in three different pituitary sections for each mouse, and the average was calculated. Results were analyzed by two-way ANOVA followed by post hoc comparisons with Fisher's PLSD test. Data are presented as mean7s.e.m. hpg, uninjected hpg mice; 10C and 50C, HSV.GFP-injected hpg mice 10 and 50 days post-injection; 10G and 50G, HSV.GnRH.GFP-injected hpg mice 10 and 50 days post-injection; WT, wild-type mice; *Po0.05 vs hpg; **Po0.05 vs 10G.
Regulated gene therapy for hypogonadism K-H Jeong et al vaginal opening. One of these mice showed persistent cornified cells typical of estrus for 16 days, after which the cell morphology returned to that of non-estrus before killing. A second mouse also showed the cornified cell types of estrus. Interestingly, this mouse subsequently developed the full spectrum of changes in cell morphology typically observed during estrous cyclicity, although at a slower rate than the normal 4-5 days observed in wild-type mice. These changes occurred for five cycles, with an average cycle duration of 23.673.8 days, lasting for a total of 118 days from the onset of the initial estrus. During this period, the average duration of estrus in each cycle was 13.473.4 days. These changes indicate the recovery of ovarian cyclicity in this mouse, albeit delayed and irregular, and provide further evidence that GnRH secretion following GnRH gene delivery is regulated. However, attempts to mate this female hpg mouse with normal male mice were unsuccessful.
Kisspeptin-10 increases LH secretion in hpg mice injected with HSV.GnRH.GFP
Kisspeptins are protein products of KiSS-1, and ligands for a G protein-coupled receptor, GPR54. 31, 32 KiSS-1 is expressed in the medial arcuate nucleus, anteroventral periventricular nucleus and POA of the hypothalamus, and has been shown recently to play a central role in the stimulation of GnRH secretion from GnRH neurons. [33] [34] [35] [36] [37] Its C-terminally amidated decapeptide fragment, kisspeptin-10, has full biologic activity as an activator of GPR54 and is a potent stimulator of hypothalamic GnRH secretion and hypothalamic-pituitary-gonadal axis activation. 35, 36, [38] [39] [40] To test whether GnRH secretion could be stimulated by kisspeptin-10 in HSV.GnRH.GFP-injected hpg mice, we treated them with kisspeptin-10 and measured their plasma LH levels ( Figure 6 ). Diestrus wild-type mice were injected with kisspeptin-10 as a positive control, resulting in markedly increased plasma LH levels, consistent with previous reports. 39, 40 HSV.GFP-injected female hpg mice did not show any change in plasma LH levels in response to kisspeptin-10. In contrast, kisspeptin-10 administration to HSV.GnRH.GFP-injected hpg females resulted in a significant increase in their plasma LH levels compared to vehicle administration, although the absolute levels of plasma LH remained below those in wild-type females. These data demonstrate that GnRH produced following HSV.GnRH.GFP injection in female hpg mice is induced by kisspeptin-10, supporting regulated GnRH production in these mice.
Discussion
This study focuses on delivery of a regulated gene for therapy of a neuroendocrine disorder. We have shown uninjected hpg mice (n ¼ 19-34) , HSV.GFP-(n ¼ 3-6) and HSV.GnRH.GFP-injected (n ¼ 6-15) hpg mice 10 and 50 days postinjection, and wild-type mice (n ¼ 11-13). Results were analyzed by two-way ANOVA followed by post hoc comparisons with Fisher's PLSD test. Data are presented as mean7s.e.m. Estradiol, 17b-estradiol; hpg, uninjected hpg mice; 10C and 50C, HSV.GFP-injected hpg mice 10 and 50 days post-injection; 10G and 50G, HSV.GnRH.GFP-injected hpg mice 10 and 50 days post-injection; WT, wild-type mice; *Po0.05 vs hpg. 
GFP-injected hpg mouse 50 days post-injection (c). (B)
Combined ovarian and uterine weights in uninjected hpg mice (n ¼ 3), HSV.GFP-(n ¼ 3) and HSV.GnRH.GFPinjected (n ¼ 7-9) hpg mice 10 and 50 days post-injection, and wild-type mice (n ¼ 6). Results were analyzed by two-way ANOVA followed by post hoc comparisons with Fisher's PLSD test. Data are presented as mean7s.e.m. hpg, uninjected hpg mice; 10C and 50C, HSV.GFP-injected hpg mice 10 and 50 days post-injection; 10G and 50G, HSV.GnRH.GFP-injected hpg mice 10 and 50 days post-injection; WT, wild-type mice; *Po0.05 vs hpg.
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that vector-mediated delivery of the GnRH gene with its cognate promoter and regulatory elements to the hypothalamic POA of adult female hpg mice yielded selective GnRH expression and improvement in reproductive parameters. Indeed, our data show that hypothalamic injection of the HSV.GnRH.GFP into the POA drives GnRH gene expression in only a subset of neurons with the expected distribution and pattern of GnRH neurons, whereas GFP is expressed more widely, supporting the integrity of the GnRH promoter and validating the use of a gene's cognate promoter in directing expression to critical neurons. Moreover, the demonstration of GnRH in POA neurons in the expected location indicates that neurons capable of supporting GnRH expression are present in hpg mice, despite their absence of endogenous GnRH production. GnRH regulation of gonadotropin biosynthesis and secretion is critically dependent on the pattern of GnRH delivery to the anterior pituitary. The normally pulsatile release of GnRH results in the stimulation of gonadotropin subunit mRNA levels and of LH and FSH synthesis and secretion, whereas either continuous or lack of exposure to GnRH generally results in downregulation of mRNA and protein levels with a consequent decrease in secretion. [41] [42] [43] [44] Phenotypic reversal of hypogonadism was achieved by intermittent intravenous GnRH injection in hpg mice. 23 In contrast, continuous GnRH administration failed to increase pituitary or plasma levels of LH. 30 Following injection of HSV.GnRH.GFP into the POA of hpg mice in this study, the numbers of LHb-and FSHb-positive pituitary cells and the plasma levels of both LH and FSH were increased. These results indicate that the GnRH staining in hypothalamic neurons following HSV.GnRH.GFP injection represents biologically active, functional GnRH, and that GnRH secretion is likely appropriately and coordinately regulated to result in intermittent or pulsatile release of GnRH into the hypophysial portal circulation and delivery to the anterior pituitary, ultimately stimulating gonadotropin production and secretion into the systemic circulation. Another indication of the reproductive improvement in HSV.GnRH.GFP-injected hpg mice is the increase in plasma estradiol levels and ovarian and uterine weights, reflecting increases in circulating levels of biologically active LH and FSH.
LH secretion is increased in response to kisspeptin-10 administration in hpg mice injected with the HSV.GnRH.GFP, but not in hpg mice injected with control vector. The lack of induction of plasma LH levels in response to kisspeptin-10 in control vector-injected female hpg mice is consistent with their lack of GnRH, and our results provide confirmation of the proposed essential role of GnRH in mediating the stimulatory effects of kisspeptin-10 on LH secretion. 45 The increase in LH secretion reflects the induction of hypothalamic GnRH secretion following kisspeptin-10 stimulation in the HSV.GnRH.GFP-injected hpg mice, providing further evidence that GnRH secretion from the targeted GnRH neurons is hormonally regulated in these mice.
Most notable is the evidence of estrous changes in vaginal smears and of estrous cyclicity in a subset of hpg mice injected with the vector carrying the GnRH gene. These changes reflect appropriate cyclical changes in circulating gonadotropin levels and gonadal steroid hormone production. In particular, estrous cyclicity provides evidence of regulation of GnRH, with positive and negative feedback modulation by gonadal steroid hormones, providing the basis of complete recapitulation of the reproductive cycle. In contrast, while it has been demonstrated that grafts of normal fetal POA tissue placed in the third ventricle of adult hpg mice can lead to increased pituitary gonadotropin secretion and gonadal weights and persistent estrus, estrous cyclicity was not achieved. 24 Taken together, the data from our study indicate that GnRH gene delivery is effective in improving reproductive function in adult female hpg mice.
Despite these overall positive effects, however, the level of GnRH expression and the degree of improvement in reproductive function in the GnRH genedelivered adult female hpg mice was not complete when compared to levels in wild-type mice. One possible explanation is that the number of GnRH neurons available for targeting is reduced in hpg mice. Supporting this hypothesis, a previous study using a retrograde tracer reported that the number of GnRH neurons detected in the POA and anterior hypothalamic area of hpg mice is only 16% of those in normal mice. 46 Consistent with these reports, the number of GnRHpositive neurons detected in HSV.GnRH.GFP-injected mice was quite small in our study, although sufficient to improve at least some aspects of reproductive function. The number of surviving GnRH neurons after fetal POA tissue grafting in hpg mice was highly variable, ranging between 3-140. 47 As few as three detectable GnRHexpressing neurons in the graft were sufficient to induce at least partial reproductive recovery. These reports underscore the ability of even a small number of GnRH neurons to maintain reproductive capacity.
Alternatively, it is possible that the effective duration of transgene persistence delivered by the HSV amplicon vector in the GnRH neurons may not be sufficient to achieve prolonged expression of GnRH, due to the extrachromosomal location of the transgene. More stable gene expression may be possible by delivery of the GnRH gene using an HSV/AAV vector. 11 In this hybrid Figure 6 Kisspeptin-10 increases LH secretion in hpg mice injected with HSV.GnRH.GFP. Plasma levels of LH in HSV.GFP-(n ¼ 3) and HSV.GnRH.GFP-injected (n ¼ 9) hpg mice and wild-type mice (n ¼ 6) 15 min after intraperitoneal administration of 10 nmol/200 ml kisspeptin-10. Results were analyzed by one-tailed Wilcoxonmatched pairs rank test for the comparison between vehicle (PBS) and kisspeptin-10 treatments in each group. Data are presented as mean7s.e.m. GFP, HSV.GFP-injected hpg mice; GnRH.GFP, HSV.GnRH.GFP-injected hpg mice; WT, wild-type mice; *Po0.05 vs vehicle.
Regulated gene therapy for hypogonadism K-H Jeong et al vector, the transgene is flanked by AAV inverted terminal repeat elements, and targeted integration can be achieved into the human genome in the AAV integration site 1 (AAVS1) on human chromosome 19q13.3-qter 48 or in AAVS1 transgenic mice 49 with expression of AAV regulatory proteins. Use of an HSV/AAV amplicon vector in AAVS1 transgenic mice crossed to hpg mice could result in more prolonged and stable expression of the GnRH gene, thus allowing greater improvement in reproductive parameters in hpg mice.
In summary, this is the first example of the correct targeting of a gene with its cognate promoter to neurons resulting in regulated expression of a biologically active peptide to our knowledge. This study demonstrates the success of this gene delivery approach in restoring GnRH expression, improving reproductive function and even establishing estrous cyclicity in a subset of treated mice. This study suggests that the presence of GnRH may not absolutely be essential for the GnRH neuronal maturation and establishment of appropriate interneuronal connections and function, although it remains possible that the quantity of GnRH neurons in the POA of hpg mice is reduced compared to wild-type mice with an intact GnRH gene. Our results also provide additional evidence for the essential role of GnRH in mediating the stimulatory effects of kisspeptin-10 on LH secretion in vivo. Finally, this study serves as a model for the efficacy of this HSV amplicon vector for selective and regulated gene replacement therapy, and thus may have a wide range of applications in the treatment of neurologic and other disorders where normal gene regulation is critical.
Materials and methods

Animal husbandry
All mice were maintained in a 12:12 h light/dark cycle. Mice heterozygous for the hpg gene deletion (C3H/ HeHx101/H background) were obtained from The Jackson Laboratory (Bar Harbor, ME, USA) and were bred to generate hpg homozygous, heterozygous, and wild-type mice. Genotyping of the offspring mice was performed by PCR using genomic DNA from the tips of mouse tails with three primers: primer 1: 5 0 -TATGGCTT ACAGTTCCAGCG (sense, intron two, upstream of the deletion); primer 2: 5 0 -AGGCTTGGAGAGCTGTAAGG (antisense, intron two, within the deleted region); primer 3: 5 0 -GTTTCAGTGCATCCTCTCAGG (antisense, downstream of the deleted region). Primers 1 and 2 are expected to generate a PCR product of 613 bp in size from the wild-type allele, and primers 1 and 3 are expected to generate a 536 bp product from the mutant allele.
Adult (2-6 month-old) female homozygous hpg or wild-type littermates were used for experiments. All experiments were approved by the Harvard Medical Area Standing Committee on Animals in the Harvard Medical School Center for Animal Resources and Comparative Medicine.
Generation of HSV.GnRH.GFP amplicon
The HSV-1 amplicon containing the 13.5 kb GnRH gene fragment with its cognate promoter (HSV.GnRH.GFP) is illustrated in Figure 1 . The vector called pmus, which is a Bluescript plasmid containing the 4 exons and 3 intervening introns (5 kb total) of the GnRH gene, together with 5 kb of 5 0 -flanking sequence and 3.5 kb of 3 0 -flanking sequence was kindly provided by Dr Peter Seeburg (University of Heidelberg, Heidelberg, Germany). This vector was digested with SalI enzyme, blunt-ended, and the NotI adaptor was added. The NotIBstEII fragment from this vector, flanking the 13.5 kb GnRH gene fragment and its promoter, was cloned into HSV.GN amplicon vector, 15, 49 which was digested with NotI and BstEII enzymes, generating 21 kb HSV.GnRH.GFP vector. To incorporate the NotI site in HSV.GN amplicon, the vector was digested with DraIII enzyme, blunt-ended and the NotI adaptor was added. The amplicons were packaged using a helper virus-free packaging system, purified through a 0.85 mm filter, and concentrated.
14 The titer of the packaged HSV.GnRH.GFP amplicon vector was 1.7 Â 10 8 transducing unit (tu)/ml. The control amplicon vector, HSV.GFP, was also generated at similar titers.
Amplicon injections
Adult female hpg mice were injected with either the HSV.GnRH.GFP or the control HSV.GFP amplicon vector (3.4 Â 10 5 tu in 2 ml) into the hypothalamic POA under pentobarbital anesthesia using a stereotaxic apparatus (Stoelting, Wood Dale, IL, USA) with the aid of a syringe pump (Stereotaxic Injector, Stoelting) and a Hamilton microliter syringe (5 ml volume, 26S gauge). Injection coordinates relative to the bregma were anterior 0.1 mm, ventral 5 mm and lateral 0 mm. After recovery, vaginal cytology was monitored on a daily basis to evaluate estrous cyclicity until killing.
Sample collection
Blood samples (300-400 ml) were collected without anesthesia by retro-orbital sinus phlebotomy into heparinized capillary tubes as reported previously, 50 before and 10 or 50 days after amplicon vector injection. Samples were collected within 3 h after lights-on to minimize fluctuation of gonadotropin levels in the wildtype females. Collected blood samples were separated immediately at 41C by centrifugation and plasma was stored at À801C in aliquots until analyses.
Following blood collection, mice in the 10-or 50-day groups and wild-type female mice were anesthetized with pentobarbital, perfused through the heart with 4% formaldehyde containing 0.2% picric acid in phosphatebuffered saline (PBS), and brain, pituitary, ovaries, uterus and adrenal glands were collected. The wet weights of ovaries, uterus and adrenal glands were measured. Brain and pituitary tissues were maintained in 4% formaldehyde with 0.2% picric acid in PBS at 41C overnight, transferred to 25% sucrose in PBS at 41C, and stored until sectioning.
Immunohistochemistry
Brain sections spanning the POA were cut at 30 mm thickness with a cryostat (Microm Laborgeräte GmbH, Walldorf, Germany), and the free-floating sections were stored in a storage solution (20 Pituitary samples were serial-sectioned at 10 mm thickness with a cryostat, and were thaw-mounted onto precleaned microscope slides (Superfrost Plus, Fisher Scientific). Sectioned slides were stored at À201C with desiccant until staining. The sections were stained with polyclonal goat anti-lutropin (for LHb subunit, Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:4000 dilution) or anti-rat FSHb antibody (AFP7798-1289, purchased from Dr Albert F Parlow, National Hormone and Peptide Program, Torrance, CA, USA; 1:50 000 dilution) in PBS containing 0.3% Triton X-100 and 1% normal horse serum, and developed and stained as described above. The number of pituitary cells positive for LHb or FSHb was counted in 680 Â 540 mm fields of three different pituitary sections for each mouse, and the average was calculated.
Kisspeptin-10 injection
Mouse KiSS-1 (110-119) amide (Phoenix Pharmaceuticals, Belmont, CA, USA) was prepared in PBS. A subset of hpg mice was injected intraperitoneally with 10 nmol/ 200 ml of kisspeptin-10 at 0900 h, 3 weeks post-vector injection. These same mice were subjected to injection of the same volume of PBS (vehicle) 7 days later. Wild-type control littermates were also injected with the same dose of kisspeptin-10 in diestrus, followed by vehicle injection two estrous cycles later, again in diestrus. Blood samples were collected 15 min after injection as described above.
Plasma hormone analyses
Immunoreactive plasma LH levels were measured using a sensitive sandwich immunoradiometric assay (IRMA) by University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core Laboratory (Charlottesville, VA, USA). The sensitivity of the assay was 0.04-0.07 ng/ml, and the intra-and inter-assay coefficients of variance (CV) were 3.6 and 11.1%, respectively. Immunoreactive plasma FSH levels were measured using a commercial rat FSH IRMA kit (Alpco Diagnostics, Windham, NH, USA), according to the manufacturer's instructions. The sensitivity of the assay was 0.2 ng/ml, and the intra-and inter-assay CV were 2.9 and 7.8%, respectively. Immunoreactive plasma estradiol levels were measured using a commercial 17b-estradiol radioimmunoassay kit (MP Biomedicals, Orangeburg, NY, USA), according to the manufacturer's instructions. The intra-and inter-assay CV were 10.6 and 11.9%, respectively.
Statistical analyses
Results were analyzed by two-way analysis of variance (ANOVA) followed by post hoc comparisons with Fisher's protected least significant difference (PLSD) test for multiple comparisons, using statistical software StatView (version 4.51, Abacus Concepts, Berkeley, CA, USA). The wild-type control group was not included in statistical analyses except in the kisspeptin-10 experiment. Results of the kisspeptin-10 experiment were analyzed by onetailed Wilcoxon matched pairs rank test for the comparison between vehicle and kisspeptin-10 treatments in the same genotype, using statistical software Prism (version 3.0, GraphPad Software, San Diego, CA, USA). A P-value o0.05 was considered statistically significant. All data are presented as the mean7s.e.m.
